San Diego, United States
TRIO Pharmaceuticals, Inc., founded in 2018 and headquartered in the United States, is revolutionizing cancer treatment with its innovative slogan: "Outsmart Cancer."
The company is pioneering a new approach in the biotechnology and healthcare sectors by developing single-agent dual-action treatments. Unlike traditional cancer drugs that can lead to toxicity and inefficacy, TRIO addresses both cancer cell growth and immunosuppression simultaneously without targeting the immune checkpoint axis. This strategy is designed to benefit patients who exhibit resistance to standard immune checkpoint treatments. Their solution holds the promise of improved efficacy, reduced toxicity, and greater affordability.
The recent $2.20M Seed Round investment on 28 March 2023 underscores investor confidence, with backing from Tech Coast Angels, SeedFolio, Newsight Tech Angels, Purdue Foundry, and Friedman BioVentures. As a company driven by a team experienced in successful drug development, TRIO is well-positioned to make a significant impact in the fight against cancer.
